Becerra Extends COVID-19 Public Health Emergency Through Mid-January

The COVID-19 national public health emergency (PHE) has been extended for a seventh time, to Jan. 13, 2022.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Friday extended the COVID-19 national public health emergency (PHE) for a seventh 90-day period.

Becerra’s Oct. 15 declaration means the PHE will last until Jan. 13, 2022, unless terminated

Read More »

340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look

Ted Slafsky
If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Read More »
Industry Insights Logo

Patient Centered Care: It’s All About the Partnerships

SPONSORED CONTENT

If you work for an organization specializing in HIV care and/or prevention, you no doubt work incredibly hard to ensure you provide care that is patient-focused in an environment that is affirming and welcoming. I can imagine on your clinic’s walls there are informational posters about the importance of

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Ben Kelly, RPh, MBA, VP of Pharmacy Operations, Maxor Pharmacy Management

Ben Kelly

Q: Where did you grow up?

I grew up in Winter Garden, FL just outside of Orlando where I still reside. My kids go to the same high school my wife and I attended.

Q: Where did you go to college/graduate school?

I received my pharmacy degree from the University of Georgia. My MBA was through Crummer School

Read More »

News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases

A federal district judge yesterday denied Sanofi's emergency request for a stay against 340B ADR proceedings, in part because she said she will rule in Sanofi's 340B contract pharmacy lawsuit on or before Nov. 5.

A federal district judge in New Jersey has denied drug manufacturer Sanofi’s emergency motion for a stay against 340B administrative dispute resolution (ADR) proceedings—in part because she said she will hand down her decision in Sanofi’s 340B contract pharmacy lawsuit

Read More »

In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power

HHS is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including for 340B.

The U.S. Health and Human Services Department (HHS) is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including those for the 340B program.

During the Trump administration, the U.S Health

Read More »

A Closer Look at Critical Court Hearing on 340B Contract Pharmacy Legality

A federal district court in Washington, D.C., heard arguments this week in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

U.S. District Judge Dabney Friedrich all but told the federal government during a court hearing in Washington, D.C., on Tuesday she rejects its basic argument that the plain text of the 340B statute requires drug manufacturers to honor 340B purchases

Read More »

Feds Oppose Sanofi’s Request for Emergency Protection Against 340B ADR Proceedings

The federal government yesterday opposed Sanofi's request to a judge to grant it emergency protection from 340B dispute resolution proceedings.

The federal government yesterday asked a federal district judge to deny drug manufacturer Sanofi’s request for emergency protection from being brought before a 340B administrative dispute resolution panel.

Sanofi asked the judge for an emergency stay last week. The

Read More »

Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes

The 340B orphan drug exclusion incentivizes manufacturers to get orphan designations for drugs approved to treat common diseases or conditions, a new government report says.

The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services

Read More »

340B Coalition Says It Will Hold 2022 Winter Conference in-Person

The 340B Coalition is holding its 2022 winter conference in person in San Diego.

The 340B Coalition announced Tuesday that its annual winter conference will be held in person Jan. 31 to Feb. 2, 2022, in San Diego. Its last, pre-pandemic in-person conference was Feb. 10-12, 2020, also in San Diego.

Apexus, the 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live